Arbutus Biopharma (ABUS) Misses Q1 EPS by 8c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.47), $0.08 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $220 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue
• Arbutus plans $230M share repurchase via Dutch auction tender offer